Z Gastroenterol 2015; 53(2): 139-142
© Georg Thieme Verlag KG Stuttgart · New York
Gemeinsame Stellungnahme der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Innere Medizin (DGIM) zur Daclatasvir-Nutzenbewertung gemäß § 35a SGB V des G-BA
Literaturverzeichnis
1 Vermehren J, Schlosser B, Domke D et al. High Prevalence of Anti-HCV Antibodies in Two Metropolitan Emergency Departments in Germany: A Prospective Screening Analysis of 28,809 Patients. Plos One 2012; 7 (7)
2 Razavi H, Waked I, Sarrazin C et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014; 21 (Suppl. 01) 34-59
3 Poethko-Muller C, Zimmermann R, Hamouda O et al. Epidemiology of hepatitis A, B, and C among adults in Germany. Results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 2013; 56 (5-6) 707-15
4 Niederau C, Bemba G, Kautz A. [Changes in socio-economics, quality of life and knowledge of patients with chronic hepatitis C during the Hepatitis Competence Net Project]. Z Gastroenterol 2008; 46 (1) 22-33
5 Huppe D, Zehnter E, Mauss S et al. Epidemiology of chronic hepatitis C in Germany – An analysis of 10 326 patients in hepatitis centres and outpatient units. Z Gastroenterol 2008; 46 (1) 34-44
6 Lee MH, Yang HI, Lu SN et al. Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study. Journal of Infectious Diseases 2012; 206 (4) 469-477
7 van der Meer AJ, Wedemeyer H, Feld JJ et al. Is there sufficient evidence to recommend antiviral therapy in hepatitis C?. Journal of Hepatology 2014; 60 (1) 191-196
8 Hill AM, Saleem J, Heath KA et al. Effects of Sustained Virological Response (SVR) on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 23,309 patients with Hepatitis C infection. Hepatology 2014; 60: 218a-9a
9 van der Meer AJ, Veldt BJ, Feld JJ et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Jama 2012; 308 (24) 2584-2593
10 van der Meer AJ, Wedemeyer H, Feld JJ et al. Life Expectancy in Patients With Chronic HCV Infection and Cirrhosis Compared With a General Population. Jama-Journal of the American Medical Association 2014; 312 (18) 1927-1928
11 Wedemeyer H, Duberg AS, Buti M et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014; 21 (Suppl. 01) 60-89
12 Sarrazin C, Berg T, Ross RS et al. Prophylaxis, Diagnosis and Therapy of Hepatitis C Virus (HCV) Infection: The German Guidelines on the Management of HCV Infection. Z Gastroenterol 2010; 48 (2) 289-351
13 Niederau C, Huppe D, Zehnter E et al. Chronic hepatitis C: Treat or wait? Medical decision making in clinical practice. World Journal of Gastroenterology 2012; 18 (12) 1339-1347
14 Heidrich B, Wiegand SB, Buggisch P et al. Treatment of Naive Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA. Plos One 2014; 9 (10)
15 Sarrazin C. Practice Recommendation for the Treatment of Chronic Hepatitis C – Approval of the Polymerase Inhibitor Sofosbuvir. Z Gastroenterol 2014; 52 (3) 311-313
16 Hezode C, Fontaine H, Dorival C et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. Journal of Hepatology 2013; 59 (3) 434-441
17 Maasoumy B, Port K, Markova AA et al. Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting. Plos One 2013; 8 (02)
18 Wedemeyer H. [Treatment of hepatitis C : What is known?]. Internist (Berl) 2014; 55 (12) 1419-1426
19 Sulkowski MS, Jacobson IM, Nelson DR. Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med 2014; 370 (16) 1560-1561
20 Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370 (20) 1889-1898
21 Jensen DM, O'Leary JG, Pockros PJ et al. Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience in a Diverse, Longitudinal Observational Cohort. Hepatology 2014; 60: 219a-220a
22 Welzel TM, Dultz G, Zeuzem S. Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. Journal of Hepatology 2014; 61: S98-S107
23 Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3. New England Journal of Medicine 2014; 370 (21) 1993-2001
24 Lawitz E, Sulkowski MS, Ghalib R et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384 (9956) 1756-1765
25 Dieterich D, Bacon BR, Flamm SL et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology 2014; 60: 220a-a
26 Lok AS, Gardiner DF, Lawitz E et al. Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1. New England Journal of Medicine 2012; 366 (3) 216-224
27 Kumada H, Suzuki Y, Ikeda K et al. Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection. Hepatology 2014; 59 (6) 2083-2091
28 Manns M, Pol S, Jacobson IM et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384 (9954) 1597-1605
29 Muir APF editor LB 2; All-oral fixed dose combination therapy with daclatasvir / asunaprevir / BMS 791 325 +/- for patients with chronic HCV genotype 1 infection and compensated cirrhosis:UNITY-2 Phase 3 SVR12 resutls. AASLD 2014; 2014 Boston:
30 Poordad FSW editor LB-7; All-oral,fixed-dose combination therapy with daclatasvir / asunaprevir / BMS791325 for non-cirrhotic patients with chronic HCV genotype 1 infection: UNITY-1 Phase3 SVR12 results. AASLD 2014; 2014 Boston:
31 Nelson DR, Cooper JN editor LB3; All-oral 12-week combination treatment with daclatasvir (DCV) and sofosbuvir (SOF) in patients infected with HCV genotype 3: ALLY-3 Phase 3 study. AASLD 2014; 2014 Boston:
32 van der Meer AJ, Farid WRR, Sonneveld MJ et al. Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122. Journal of Viral Hepatitis 2013; 20 (3) 158-166
